Skip to main content
Fig. 5 | BMC Nephrology

Fig. 5

From: Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4–5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial

Fig. 5

Effect of treatment on renal function. The bumetanide plus placebo group is shown in blue (control group), and the bumetanide plus chlorthalidone group is shown in red (intervention group). A Regarding serum creatinine, the intervention group showed a significant increase at Day 7 (p = 0.001) and Day 30 (p < 0.000). B Regarding GFR, a significant decrease in the intervention group was observed at Day 7 (p = 0.004) and Day 30 (p = 0.003). C Serum urea levels in both groups showed significant increases when comparing baseline versus Days 7 and 30 (control group, p = 0.02 and p < 0.000, respectively, and intervention group, p = 0.008 and p < 0.000, respectively)

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us